This study looks at how a medicine called isatuximab works with other new medicines for people with a type of cancer called relapsed or refractory myeloma (RRMM). Myeloma is when cancer cells build up in the bone marrow, and "relapsed or refractory" means the disease came back or didn't respond to treatment. There are different parts of the study, some with and some without another drug called dexamethasone, which is used to reduce inflammation.

Participants will stay on the study until their disease gets worse, they experience harmful side effects, or they choose to stop. The study could last up to 28 months.

• Participants must be 18 or older and should have already tried at least two different treatments for myeloma.
• The study involves regular health checks and tests to monitor progress and safety.
• Participants must agree to use birth control to prevent pregnancy during the study.

Before joining, discuss with your doctor to understand the risks and benefits. Your participation could help find better treatments for myeloma.